Efficient use of exogenous isoprenols for protein isoprenylation by MDA-MB-231 cells is regulated independently of the mevalonate pathway

Journal of Biological Chemistry

Volumn 288, Issue 38, 2013, Pages 27444-27455

  Onono, Fredrick ^a   Subramanian, Thangaiah ^a   Sunkara, Manjula ^b   Subramanian, Karunai Leela ^b   Peter Spielmann, H ^a   Morris, Andrew J ^b,c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c LEXINGTON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANILINE; BIOSYNTHESIS; CELL CULTURE; DISEASES; DRUG PRODUCTS; LIPIDS; MAMMALS; MASS SPECTROMETRY; PROTEINS;

BREAST CANCER CELLS; HMG-COA REDUCTASE; HUMAN CANCER CELLS; MDA-MB-231 CELLS; MEVALONATE PATHWAY; MUTATIONAL ACTIVATION; PHARMACOLOGICAL INHIBITION; THERAPEUTIC BENEFITS;

CELLS;

ANILINOFARNESOL DIPHOSPHATE; ANILINOGERANIOL DIPHOSPHATE; CYSTEINE DERIVATIVE; FARNESOL; GERANYLGERANIOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; ISOPRENALINE; ISOPRENOID; ISOPRENOID DIPHOSPHATE; ISOPRENYLCYSTEINE; MEVALONIC ACID; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL METABOLISM; CONTROLLED STUDY; HUMAN; HUMAN CELL; ISOTOPE LABELING; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN PRENYLATION; REGULATORY MECHANISM; TUMOR INVASION; UPREGULATION;

MAMMALIA;

EID: 84884578809     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.482307     Document Type: Article

References (25)

1. Goldstein, J. L., and Brown, M. S. (1990) Regulation of the mevalonate pathway. Nature 343, 425-430
2. Miriyala, S., Subramanian, T., Panchatcharam, M., Ren, H., McDermott, M. I., Sunkara, M., Drennan, T., Smyth, S. S., Spielmann, H. P., and Morris, A. J. (2010) Functional characterization of the atypical integral membrane lipid phosphatase PDP1/PPAPDC2 identifies a pathway for interconversion of isoprenols and isoprenoid phosphates in mammalian cells. J. Biol. Chem. 285, 13918-13929
3. Chang, S. Y., Hudon-Miller, S. E., Yang, S. H., Jung, H. J., Lee, J. M., Farber, E., Subramanian, T., Andres, D. A., Spielmann, H. P., Hrycyna, C. A., Young, S. G., and Fong, L. G. (2012) Inhibitors of protein geranylgeranyltransferase-I lead to prelamin A accumulation in cells by inhibiting ZMPSTE24. J. Lipid Res. 53, 1176-1182
4. Yang, S. H., Chang, S. Y., Ren, S., Wang, Y., Andres, D. A., Spielmann, H. P., Fong, L. G., and Young, S. G. (2011) Absence of progeria-like disease phenotypes in knock-in mice expressing a non-farnesylated version of progerin. Hum. Mol. Genet. 20, 436-444
5. Onono, F. O., Morgan, M. A., Spielmann, H. P., Andres, D. A., Subramanian, T., Ganser, A., and Reuter, C. W. (2010) A tagging-via-substrate approach to detect the farnesylated proteome using two-dimensional electrophoresis coupled with Western blotting. Mol. Cell. Proteomics 9, 742-751
6. Troutman, J. M., Roberts, M. J., Andres, D. A., and Spielmann, H. P. (2005) Tools to analyze protein farnesylation in cells. Bioconjug. Chem. 16, 1209-1217
7. Fliesler, S. J., and Keller, R. K. (1995) Metabolism of [3H]farnesol to cholesterol and cholesterogenic intermediates in the living rat eye. Biochem. Biophys. Res. Commun. 210, 695-702
8. Ownby, S. E., and Hohl, R. J. (2002) Farnesol and geranylgeraniol: prevention and reversion of lovastatin-induced effects in NIH3T3 cells. Lipids 37, 185-192
9. Crick, D. C., Andres, D. A., Danesi, R., Macchia, M., and Waechter, C. J. (1998) Geranylgeraniol overcomes the block of cell proliferation by lovastatin in C6 glioma cells. J. Neurochem. 70, 2397-2405
10. Thurnher, M., Nussbaumer, O., and Gruenbacher, G. (2012) Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clin. Cancer Res. 18, 3524-3531
11. Zhou, Q., and Liao, J. K. (2010) Pleiotropic effects of statins. Basic research and clinical perspectives. Circ. J. 74, 818-826
12. Buettner, C., and Lecker, S. H. (2008) Molecular basis for statin-induced muscle toxicity: implications and possibilities. Pharmacogenomics 9, 1133-1142
13. Nielsen, S. F., Nordestgaard, B. G., and Bojesen, S. E. (2012) Statin use and reduced cancer-related mortality. N. Engl. J. Med. 367, 1792-1802
14. Nielsen, S. F., Nordestgaard, B. G., and Bojesen, S. E. (2013) Cancer patients should not be treated with statins. Reply. Ugeskr. Laeger 175, 76
15. Freed-Pastor, W. A., Mizuno, H., Zhao, X., Langerød, A., Moon, S. H., Rodriguez-Barrueco, R., Barsotti, A., Chicas, A., Li, W., Polotskaia, A., Bissell, M. J., Osborne, T. F., Tian, B., Lowe, S. W., Silva, J. M., Børresen-Dale, A. L., Levine, A. J., Bargonetti, J., and Prives, C. (2012) Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148, 244-258
16. Subramanian, T., Parkin, S., and Spielmann, H. P. (2012) Synthesis of farnesol analogues containing triazoles in place of isoprenes through "click chemistry." Synlett 23, 2539-2543
17. Subramanian, T., Pais, J. E., Liu, S., Troutman, J. M., Suzuki, Y., Leela Subramanian, K., Fierke, C. A., Andres, D. A., and Spielmann, H. P. (2012) Farnesyl diphosphate analogues with aryl moieties are efficient alternate substrates for protein farnesyltransferase. Biochemistry 51, 8307-8319
18. Subramanian, T., Subramanian, K. L., Sunkara, M., Onono, F. O., Morris, A. J., and Spielmann, H. P. (2013) Syntheses of deuterium labeled prenyldiphosphate and prenylcysteine analogues for in vivo mass spectrometric quantification. J. Labelled Comp. Radiopharm. 56, 370-375
19. Tong, H., Holstein, S. A., and Hohl, R. J. (2005) Simultaneous determination of farnesyl and geranylgeranyl pyrophosphate levels in cultured cells. Anal. Biochem. 336, 51-59
20. Holstein, S. A., Tong, H., Kuder, C. H., and Hohl, R. J. (2009) Quantitative determination of geranyl diphosphate levels in cultured human cells. Lipids 44, 1055-1062
21. Thai, L., Rush, J. S., Maul, J. E., Devarenne, T., Rodgers, D. L., Chappell, J., and Waechter, C. J. (1999) Farnesol is utilized for isoprenoid biosynthesis in plant cells via farnesyl pyrophosphate formed by successive monophosphorylation reactions. Proc. Natl. Acad. Sci. U. S. A. 96, 13080-13085
22. Keller, R. K., Zhao, Z., Chambers, C., and Ness, G. C. (1996) Farnesol is not the nonsterol regulator mediating degradation of HMG-CoA reductase in rat liver. Arch. Biochem. Biophys. 328, 324-330
23. Beigneux, A., Withycombe, S. K., Digits, J. A., Tschantz, W. R., Weinbaum, C. A., Griffey, S. M., Bergo, M., Casey, P. J., and Young, S. G. (2002) Prenylcysteine lyase deficiency in mice results in the accumulation of farnesylcysteine and geranylgeranylcysteine in brain and liver. J. Biol. Chem. 277, 38358-38363
24. Faulkner, A., Chen, X., Rush, J., Horazdovsky, B., Waechter, C. J., Carman, G. M., and Sternweis, P. C. (1999) The LPP1 and DPP1 gene products account for most of the isoprenoid phosphate phosphatase activities in Saccharomyces cerevisiae. J. Biol. Chem. 274, 14831-14837
25. Zeichner, S., Mihos, C. G., and Santana, O. (2012) The pleiotropic effects and therapeutic potential of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in malignancies: a comprehensive review. J. Cancer Res. Ther. 8, 176-183